Patience from British water technology company Modern Water and its shareholders finally looks to be paying off when rolling out its forward osmosis (FO) membrane technology globally.
The first revenue from FO sales in China have finally benefitted the company, with overall group revenue for the first half of 2017 increasing 37 percent to £1.56 million, from £1.14m the previous year.
In its interim results release today, the company described the first half of 2017 as a “milestone period” for its membrane division, with “first time revenues achieved for three separate products in three different geographic markets”.
Modern Water’s first All Membrane Brine Concentrator (AMBC) contract was completed with Indian partner, Advent Envirocare. The full plant is expected to be commissioned before the end of the year.
Regarding its FO division, the contract with Hagzhou Water Treatment Technology Development Centre has now been completed.
This project involves the FO membranes being used in a new 500 m3/day seawater desalination plant, to be built at the Shengsi Seawater Desalination Base on Sijiao Island.
Meanwhile, the first AquaPak desalination unit has been delivered, installed and commissioned in Oman.
Commenting on its partnership with Bilfinger Deutchse Babcock to combine Multi Stage Flash (MSF) with its FO technology, the company said it is in “final negotiations to deploy our first MSF pre-treatment plant to a desalination facility in the Middle East”.
Alan Wilson, chairman of Modern Water, said: “The impressive performance of our All Membrane Brine Concentrator (AMBC) in the cleaning of process waste-water for an Indian-based textiles company was widely marketed and has encouragingly resulted in new enquiries from companies in a range of countries and industrial sectors. We are also beginning to see increasing market interest in our other membrane technologies, with sales of licences and products in China, India and Oman.”
With the monitoring business having carried the company in recent years, the increase in revenue from the group’s membrane division will be welcome news for shareholders.